Circulating tumor cells are prognostic in early breast cancer

This article originally appeared here.
Share this content:
Circulating Tumor Cells Prognostic in Early Breast Cancer
Circulating Tumor Cells Prognostic in Early Breast Cancer

(HealthDay News) -- Circulating tumor cells (CTCs) are prognostic of poor survival in early breast cancer, according to a study published online May 15 in the Journal of the National Cancer Institute.

Brigitte Rack, M.D., from the Ludwig-Maximilians-University Munich in Germany, and colleagues used the CellSearch System to analyze CTCs in 2,026 patients with early breast cancer before adjuvant chemotherapy and in 1,492 patients after chemotherapy. Nucleated cells expressing cytokeratin and lacking CD45 were classified as CTCs. The median follow-up was 35 months.

The researchers found that 21.5 percent of patients had CTCs before chemotherapy, including 19.6 percent of node-negative and 22.4 percent of node-positive patients (P < 0.001). There was no correlation with tumor size, grading, or hormone receptor status. CTCs were detected in 22.1 percent of patients after chemotherapy. CTC presence correlated with poor disease-free survival (DFS), distant DFS, breast cancer-specific survival, and overall survival (OS). In multivariate analysis, CTCs were confirmed as independent prognostic markers for DFS (hazard ratio, 2.11; P < 0.0001) and OS (hazard ratio, 2.18; P = 0.002). Patients with at least five CTCs per 30 mL blood had the worst prognosis for DFS and OS (hazard ratios, 4.51 and 3.60, respectively). After chemotherapy, the presence of CTCs had a negative impact on DFS and OS (hazard ratios, 1.12 [P = 0.02] and 1.16 [P = 0.06], respectively).

"These results suggest the independent prognostic relevance of CTCs both before and after adjuvant chemotherapy in a large prospective trial of patients with primary breast cancer," the authors write.

Several authors disclosed financial ties to the pharmaceutical companies that funded the translational research part of the SUCCESS trial.

Full Text
Editorial (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs